1	4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	present	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	absorption	_	_	NN	_	_	_	_	_
8	pattern	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	pharmacokinetic	_	_	JJ	_	_	_	_	_
11	pattern	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	free	_	_	JJ	_	_	_	_	_
14	choline	_	_	NN	_	_	_	_	_
15	from	_	_	IN	_	_	_	_	_
16	Superba	_	_	NN	_	_	_	_	_
17	Boost	_	_	NN	_	_	_	_	_
18	TM	_	_	NN	_	_	_	_	_
19	krill	_	_	NN	_	_	_	_	_
20	oil	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	choline	_	_	NN	_	_	_	_	_
23	bitartrate	_	_	NN	_	_	_	_	_
24	were	_	_	VBD	_	_	_	_	_
25	investigated	_	_	VBN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	Superba	_	_	NNP	_	_	_	_	_
3	Boost	_	_	NNP	_	_	_	_	_
4	TM	_	_	NNP	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	choline	_	_	NN	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	bound	_	_	VBN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	lipid-soluble	_	_	JJ	_	_	_	_	_
12	form	_	_	NN	_	_	_	_	_
13	as	_	_	IN	_	_	_	_	_
14	phosphatidylcholine	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	while	_	_	IN	_	_	_	_	_
17	it	_	_	PRP	_	_	_	_	_
18	is	_	_	VBZ	_	_	_	_	_
19	present	_	_	JJ	_	_	_	_	_
20	as	_	_	IN	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	water-soluble	_	_	JJ	_	_	_	_	_
23	salt	_	_	NN	_	_	_	_	_
24	structure	_	_	NN	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	choline	_	_	NN	_	_	_	_	_
27	bitartrate	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Results	_	_	NNS	_	_	_	_	_
2	show	_	_	VBP	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	free	_	_	JJ	_	_	_	_	_
5	choline	_	_	NN	_	_	_	_	_
6	levels	_	_	NNS	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	plasma	_	_	NN	_	_	_	_	_
9	were	_	_	VBD	_	_	_	_	_
10	comparable	_	_	JJ	_	_	_	_	_
11	between	_	_	IN	_	_	_	_	_
12	Superba	_	_	NN	_	_	_	_	_
13	Boost	_	_	NN	_	_	_	_	_
14	TM	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	choline	_	_	NN	_	_	_	_	_
17	bitartrate	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	but	_	_	CC	_	_	_	_	_
20	peak	_	_	NN	_	_	_	_	_
21	choline	_	_	NN	_	_	_	_	_
22	concentrations	_	_	NNS	_	_	_	_	_
23	were	_	_	VBD	_	_	_	_	_
24	reached	_	_	VBN	_	_	_	_	_
25	significantly	_	_	RB	_	_	_	_	_
26	later	_	_	RBR	_	_	_	_	_
27	upon	_	_	IN	_	_	_	_	_
28	intake	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	Superba	_	_	NN	_	_	_	_	_
31	Boost	_	_	NN	_	_	_	_	_
32	TM	_	_	NN	_	_	_	_	_
33	compared	_	_	VBN	_	_	_	_	_
34	to	_	_	TO	_	_	_	_	_
35	choline	_	_	NN	_	_	_	_	_
36	bitartrate	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	levels	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	choline	_	_	NN	_	_	_	_	_
7	metabolites	_	_	NNS	_	_	_	_	_
8	betaine	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	DMG	_	_	NN	_	_	_	_	_
11	were	_	_	VBD	_	_	_	_	_
12	higher	_	_	JJR	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	while	_	_	IN	_	_	_	_	_
15	levels	_	_	NNS	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	TMAO	_	_	NNP	_	_	_	_	_
18	were	_	_	VBD	_	_	_	_	_
19	lower	_	_	JJR	_	_	_	_	_
20	upon	_	_	IN	_	_	_	_	_
21	intake	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	Superba	_	_	NN	_	_	_	_	_
24	Boost	_	_	NN	_	_	_	_	_
25	TM	_	_	NN	_	_	_	_	_
26	compared	_	_	VBN	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	choline	_	_	NN	_	_	_	_	_
29	bitartrate	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	dependency	_	_	NN	_	_	_	_	_
3	between	_	_	IN	_	_	_	_	_
4	choline	_	_	NN	_	_	_	_	_
5	intake	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	circulating	_	_	VBG	_	_	_	_	_
8	levels	_	_	NNS	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	free	_	_	JJ	_	_	_	_	_
11	choline	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	its	_	_	PRP$	_	_	_	_	_
14	metabolites	_	_	NNS	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	concealed	_	_	VBN	_	_	_	_	_
17	by	_	_	IN	_	_	_	_	_
18	homeostatic	_	_	JJ	_	_	_	_	_
19	regulations	_	_	NNS	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	rapid	_	_	JJ	_	_	_	_	_
22	tissue	_	_	NN	_	_	_	_	_
23	uptake	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	concentrations	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	choline	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	its	_	_	PRP$	_	_	_	_	_
8	metabolites	_	_	NNS	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	usually	_	_	RB	_	_	_	_	_
11	within	_	_	IN	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	narrow	_	_	JJ	_	_	_	_	_
14	range	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	literature	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	endogenous	_	_	JJ	_	_	_	_	_
6	free	_	_	JJ	_	_	_	_	_
7	fasting	_	_	VBG	_	_	_	_	_
8	choline	_	_	NN	_	_	_	_	_
9	levels	_	_	NNS	_	_	_	_	_
10	under	_	_	IN	_	_	_	_	_
11	physiological	_	_	JJ	_	_	_	_	_
12	conditions	_	_	NNS	_	_	_	_	_
13	range	_	_	VBP	_	_	_	_	_
14	between	_	_	IN	_	_	_	_	_
15	7	_	_	CD	_	_	_	_	_
16	–	_	_	TO	_	_	_	_	_
17	12	_	_	CD	_	_	_	_	_
18	µmol/L	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	which	_	_	WDT	_	_	_	_	_
21	could	_	_	MD	_	_	_	_	_
22	be	_	_	VB	_	_	_	_	_
23	confirmed	_	_	VBN	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	present	_	_	JJ	_	_	_	_	_
27	study	_	_	NN	_	_	_	_	_
28	with	_	_	IN	_	_	_	_	_
29	a	_	_	DT	_	_	_	_	_
30	mean	_	_	JJ	_	_	_	_	_
31	choline	_	_	NN	_	_	_	_	_
32	concentration	_	_	NN	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	9.6	_	_	CD	_	_	_	_	_
35	µmol/L	_	_	NN	_	_	_	_	_
36	before	_	_	IN	_	_	_	_	_
37	product	_	_	NN	_	_	_	_	_
38	intake	_	_	NN	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	baseline	_	_	NN	_	_	_	_	_
4	values	_	_	NNS	_	_	_	_	_
5	were	_	_	VBD	_	_	_	_	_
6	highly	_	_	RB	_	_	_	_	_
7	comparable	_	_	JJ	_	_	_	_	_
8	within	_	_	IN	_	_	_	_	_
9	all	_	_	DT	_	_	_	_	_
10	groups	_	_	NNS	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	within	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	two	_	_	CD	_	_	_	_	_
15	kinetic	_	_	JJ	_	_	_	_	_
16	days	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	well	_	_	RB	_	_	_	_	_
4	known	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	choline	_	_	NN	_	_	_	_	_
7	levels	_	_	NNS	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	influenced	_	_	VBN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	nutrition	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	choline	_	_	NN	_	_	_	_	_
15	sources	_	_	NNS	_	_	_	_	_
16	depend	_	_	VBP	_	_	_	_	_
17	on	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	diet	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	In	_	_	IN	_	_	_	_	_
22	a	_	_	DT	_	_	_	_	_
23	normal	_	_	JJ	_	_	_	_	_
24	Western	_	_	JJ	_	_	_	_	_
25	diet	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	choline	_	_	NN	_	_	_	_	_
28	can	_	_	MD	_	_	_	_	_
29	be	_	_	VB	_	_	_	_	_
30	obtained	_	_	VBN	_	_	_	_	_
31	from	_	_	IN	_	_	_	_	_
32	eggs	_	_	NNS	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	liver	_	_	NN	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	soybeans	_	_	NNS	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	pork	_	_	NN	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	where	_	_	WRB	_	_	_	_	_
41	choline	_	_	NN	_	_	_	_	_
42	is	_	_	VBZ	_	_	_	_	_
43	present	_	_	JJ	_	_	_	_	_
44	primarily	_	_	RB	_	_	_	_	_
45	as	_	_	IN	_	_	_	_	_
46	phosphatidylcholine	_	_	NN	_	_	_	_	_
47	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	was	_	_	VBD	_	_	_	_	_
3	shown	_	_	VBN	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	consumption	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	small	_	_	JJ	_	_	_	_	_
10	breakfast	_	_	NN	_	_	_	_	_
11	led	_	_	VBD	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	25	_	_	CD	_	_	_	_	_
14	–	_	_	TO	_	_	_	_	_
15	30	_	_	CD	_	_	_	_	_
16	%	_	_	NN	_	_	_	_	_
17	higher	_	_	JJR	_	_	_	_	_
18	choline	_	_	NN	_	_	_	_	_
19	levels	_	_	NNS	_	_	_	_	_
20	compared	_	_	VBN	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	fasting	_	_	VBG	_	_	_	_	_
24	condition	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	that	_	_	IN	_	_	_	_	_
28	a	_	_	DT	_	_	_	_	_
29	high	_	_	JJ	_	_	_	_	_
30	choline-containing	_	_	JJ	_	_	_	_	_
31	diet	_	_	NN	_	_	_	_	_
32	resulted	_	_	VBD	_	_	_	_	_
33	in	_	_	IN	_	_	_	_	_
34	an	_	_	DT	_	_	_	_	_
35	up	_	_	IN	_	_	_	_	_
36	to	_	_	TO	_	_	_	_	_
37	two-fold	_	_	JJ	_	_	_	_	_
38	increase	_	_	NN	_	_	_	_	_
39	in	_	_	IN	_	_	_	_	_
40	plasma	_	_	NN	_	_	_	_	_
41	choline	_	_	NN	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	a	_	_	DT	_	_	_	_	_
3	recent	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	Cho	_	_	NNP	_	_	_	_	_
7	et	_	_	FW	_	_	_	_	_
8	al.	_	_	FW	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	eggs	_	_	NNS	_	_	_	_	_
11	were	_	_	VBD	_	_	_	_	_
12	provided	_	_	VBN	_	_	_	_	_
13	as	_	_	IN	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	choline	_	_	NN	_	_	_	_	_
16	source	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	which	_	_	WDT	_	_	_	_	_
19	contained	_	_	VBD	_	_	_	_	_
20	comparable	_	_	JJ	_	_	_	_	_
21	amounts	_	_	NNS	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	choline	_	_	NN	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	479	_	_	CD	_	_	_	_	_
26	mg	_	_	NN	_	_	_	_	_
27	)	_	_	-RRB-	_	_	_	_	_
28	as	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	herein	_	_	NN	_	_	_	_	_
31	investigated	_	_	VBN	_	_	_	_	_
32	study	_	_	NN	_	_	_	_	_
33	products	_	_	NNS	_	_	_	_	_
34	(	_	_	-LRB-	_	_	_	_	_
35	choline	_	_	NN	_	_	_	_	_
36	bitartrate	_	_	NN	_	_	_	_	_
37	:	_	_	:	_	_	_	_	_
38	620	_	_	CD	_	_	_	_	_
39	mg	_	_	NN	_	_	_	_	_
40	;	_	_	:	_	_	_	_	_
41	Superba	_	_	NNP	_	_	_	_	_
42	Boost	_	_	NN	_	_	_	_	_
43	TM	_	_	NN	_	_	_	_	_
44	:	_	_	:	_	_	_	_	_
45	572	_	_	CD	_	_	_	_	_
46	mg	_	_	NN	_	_	_	_	_
47	)	_	_	-RRB-	_	_	_	_	_
48	.	_	_	.	_	_	_	_	_
49	Cho	_	_	NNP	_	_	_	_	_
50	et	_	_	FW	_	_	_	_	_
51	al.	_	_	FW	_	_	_	_	_
52	reported	_	_	VBD	_	_	_	_	_
53	a	_	_	DT	_	_	_	_	_
54	1.6-fold	_	_	JJ	_	_	_	_	_
55	increase	_	_	NN	_	_	_	_	_
56	in	_	_	IN	_	_	_	_	_
57	free	_	_	JJ	_	_	_	_	_
58	choline	_	_	NN	_	_	_	_	_
59	after	_	_	IN	_	_	_	_	_
60	consumption	_	_	NN	_	_	_	_	_
61	of	_	_	IN	_	_	_	_	_
62	the	_	_	DT	_	_	_	_	_
63	egg	_	_	NN	_	_	_	_	_
64	meal	_	_	NN	_	_	_	_	_
65	,	_	_	,	_	_	_	_	_
66	in	_	_	IN	_	_	_	_	_
67	comparison	_	_	NN	_	_	_	_	_
68	to	_	_	TO	_	_	_	_	_
69	the	_	_	DT	_	_	_	_	_
70	fruit	_	_	NN	_	_	_	_	_
71	control	_	_	NN	_	_	_	_	_
72	meal	_	_	NN	_	_	_	_	_
73	.	_	_	.	_	_	_	_	_


1	Correspondingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	choline	_	_	NN	_	_	_	_	_
5	increase	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	current	_	_	JJ	_	_	_	_	_
9	study	_	_	NN	_	_	_	_	_
10	upon	_	_	IN	_	_	_	_	_
11	supplement	_	_	NN	_	_	_	_	_
12	intake	_	_	NN	_	_	_	_	_
13	was	_	_	VBD	_	_	_	_	_
14	comparable	_	_	JJ	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	choline	_	_	NN	_	_	_	_	_
17	bitartrate	_	_	NN	_	_	_	_	_
18	:	_	_	:	_	_	_	_	_
19	1.35-fold	_	_	CD	_	_	_	_	_
20	;	_	_	:	_	_	_	_	_
21	Superba	_	_	NN	_	_	_	_	_
22	Boost	_	_	NN	_	_	_	_	_
23	TM	_	_	NN	_	_	_	_	_
24	:	_	_	:	_	_	_	_	_
25	1.48-fold	_	_	CD	_	_	_	_	_
26	)	_	_	-RRB-	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	control	_	_	VB	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	confounding	_	_	VBG	_	_	_	_	_
5	factors	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	food	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	subjects	_	_	NNS	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	present	_	_	JJ	_	_	_	_	_
13	study	_	_	NN	_	_	_	_	_
14	adhered	_	_	VBD	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	diet	_	_	NN	_	_	_	_	_
18	low	_	_	JJ	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	choline	_	_	NN	_	_	_	_	_
21	three	_	_	CD	_	_	_	_	_
22	days	_	_	NNS	_	_	_	_	_
23	before	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	study	_	_	NN	_	_	_	_	_
26	intervention	_	_	NN	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	consumed	_	_	VBD	_	_	_	_	_
29	standardized	_	_	VBN	_	_	_	_	_
30	meals	_	_	NNS	_	_	_	_	_
31	during	_	_	IN	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	kinetic	_	_	JJ	_	_	_	_	_
34	days	_	_	NNS	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	parallel	_	_	JJ	_	_	_	_	_
6	study	_	_	NN	_	_	_	_	_
7	arm	_	_	NN	_	_	_	_	_
8	was	_	_	VBD	_	_	_	_	_
9	included	_	_	VBN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	whose	_	_	WP$	_	_	_	_	_
12	subjects	_	_	NNS	_	_	_	_	_
13	underwent	_	_	VBD	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	single	_	_	JJ	_	_	_	_	_
16	kinetic	_	_	JJ	_	_	_	_	_
17	dose	_	_	NN	_	_	_	_	_
18	after	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	intake	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	fish	_	_	NN	_	_	_	_	_
23	oil	_	_	NN	_	_	_	_	_
24	as	_	_	IN	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	placebo	_	_	NN	_	_	_	_	_
27	control	_	_	NN	_	_	_	_	_
28	that	_	_	WDT	_	_	_	_	_
29	was	_	_	VBD	_	_	_	_	_
30	devoid	_	_	JJ	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	choline	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Of	_	_	IN	_	_	_	_	_
2	note	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	we	_	_	PRP	_	_	_	_	_
5	observed	_	_	VBD	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	minor	_	_	JJ	_	_	_	_	_
8	increase	_	_	NN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	choline	_	_	NN	_	_	_	_	_
11	levels	_	_	NNS	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	placebo	_	_	NN	_	_	_	_	_
15	group	_	_	NN	_	_	_	_	_
16	after	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	4	_	_	CD	_	_	_	_	_
19	h	_	_	NN	_	_	_	_	_
20	time	_	_	NN	_	_	_	_	_
21	point	_	_	NN	_	_	_	_	_
22	;	_	_	:	_	_	_	_	_
23	thus	_	_	RB	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	standardized	_	_	VBN	_	_	_	_	_
27	lunch	_	_	NN	_	_	_	_	_
28	served	_	_	VBD	_	_	_	_	_
29	after	_	_	IN	_	_	_	_	_
30	four	_	_	CD	_	_	_	_	_
31	hours	_	_	NNS	_	_	_	_	_
32	could	_	_	MD	_	_	_	_	_
33	have	_	_	VB	_	_	_	_	_
34	contributed	_	_	VBN	_	_	_	_	_
35	to	_	_	TO	_	_	_	_	_
36	this	_	_	DT	_	_	_	_	_
37	elevation	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	no	_	_	DT	_	_	_	_	_
4	such	_	_	JJ	_	_	_	_	_
5	effect	_	_	NN	_	_	_	_	_
6	was	_	_	VBD	_	_	_	_	_
7	seen	_	_	VBN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	study	_	_	NN	_	_	_	_	_
11	groups	_	_	NNS	_	_	_	_	_
12	receiving	_	_	VBG	_	_	_	_	_
13	choline	_	_	NN	_	_	_	_	_
14	supplements	_	_	NNS	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	by	_	_	IN	_	_	_	_	_
5	implementing	_	_	VBG	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	control	_	_	NN	_	_	_	_	_
8	group	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	we	_	_	PRP	_	_	_	_	_
11	were	_	_	VBD	_	_	_	_	_
12	able	_	_	JJ	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	exclude	_	_	VB	_	_	_	_	_
15	possible	_	_	JJ	_	_	_	_	_
16	circadian	_	_	JJ	_	_	_	_	_
17	rhythm-dependent	_	_	JJ	_	_	_	_	_
18	variations	_	_	NNS	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	choline	_	_	NN	_	_	_	_	_
21	levels	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	contrast	_	_	NN	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	Park	_	_	NNP	_	_	_	_	_
27	et	_	_	FW	_	_	_	_	_
28	al.	_	_	FW	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	who	_	_	WP	_	_	_	_	_
31	observed	_	_	VBD	_	_	_	_	_
32	a	_	_	DT	_	_	_	_	_
33	slight	_	_	JJ	_	_	_	_	_
34	elevation	_	_	NN	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	free	_	_	JJ	_	_	_	_	_
37	choline	_	_	NN	_	_	_	_	_
38	levels	_	_	NNS	_	_	_	_	_
39	in	_	_	IN	_	_	_	_	_
40	the	_	_	DT	_	_	_	_	_
41	afternoon	_	_	NN	_	_	_	_	_
42	during	_	_	IN	_	_	_	_	_
43	a	_	_	DT	_	_	_	_	_
44	12	_	_	CD	_	_	_	_	_
45	h-lasting	_	_	VBG	_	_	_	_	_
46	observation	_	_	NN	_	_	_	_	_
47	of	_	_	IN	_	_	_	_	_
48	endogenous	_	_	JJ	_	_	_	_	_
49	choline	_	_	NN	_	_	_	_	_
50	levels	_	_	NNS	_	_	_	_	_
51	.	_	_	.	_	_	_	_	_


1	Krill	_	_	NNP	_	_	_	_	_
2	oil	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	increasingly	_	_	RB	_	_	_	_	_
5	recognized	_	_	VBN	_	_	_	_	_
6	as	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	useful	_	_	JJ	_	_	_	_	_
9	source	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	phosphatidylcholine	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	addition	_	_	NN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	its	_	_	PRP$	_	_	_	_	_
17	acknowledged	_	_	VBN	_	_	_	_	_
18	role	_	_	NN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	providing	_	_	VBG	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	omega-3	_	_	JJ	_	_	_	_	_
23	fatty	_	_	NN	_	_	_	_	_
24	acids	_	_	NNS	_	_	_	_	_
25	EPA	_	_	NNP	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	DHA	_	_	NNP	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	a	_	_	DT	_	_	_	_	_
3	former	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	phosphatidylcholine	_	_	NN	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	shown	_	_	VBN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	raise	_	_	VB	_	_	_	_	_
11	plasma	_	_	NN	_	_	_	_	_
12	choline	_	_	NN	_	_	_	_	_
13	levels	_	_	NNS	_	_	_	_	_
14	more	_	_	RBR	_	_	_	_	_
15	efficiently	_	_	RB	_	_	_	_	_
16	compared	_	_	VBN	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	ingestion	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	free	_	_	JJ	_	_	_	_	_
21	choline	_	_	NN	_	_	_	_	_
22	as	_	_	IN	_	_	_	_	_
23	choline	_	_	NN	_	_	_	_	_
24	chloride	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	current	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	observed	_	_	VBD	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	significant	_	_	JJ	_	_	_	_	_
9	increase	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	choline	_	_	NN	_	_	_	_	_
12	after	_	_	IN	_	_	_	_	_
13	single	_	_	JJ	_	_	_	_	_
14	doses	_	_	NNS	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	both	_	_	CC	_	_	_	_	_
17	phosphatidylcholine	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	reference	_	_	NN	_	_	_	_	_
21	product	_	_	NN	_	_	_	_	_
22	choline	_	_	NN	_	_	_	_	_
23	bitartrate	_	_	NN	_	_	_	_	_
24	;	_	_	:	_	_	_	_	_
25	however	_	_	RB	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	phosphatidylcholine	_	_	NN	_	_	_	_	_
28	was	_	_	VBD	_	_	_	_	_
29	not	_	_	RB	_	_	_	_	_
30	more	_	_	RBR	_	_	_	_	_
31	efficient	_	_	JJ	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	since	_	_	IN	_	_	_	_	_
34	there	_	_	EX	_	_	_	_	_
35	were	_	_	VBD	_	_	_	_	_
36	no	_	_	DT	_	_	_	_	_
37	significant	_	_	JJ	_	_	_	_	_
38	differences	_	_	NNS	_	_	_	_	_
39	in	_	_	IN	_	_	_	_	_
40	the	_	_	DT	_	_	_	_	_
41	pharmacokinetic	_	_	JJ	_	_	_	_	_
42	endpoints	_	_	NNS	_	_	_	_	_
43	AUC	_	_	NNP	_	_	_	_	_
44	and	_	_	CC	_	_	_	_	_
45	Cmax	_	_	NNP	_	_	_	_	_
46	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	discrepancy	_	_	NN	_	_	_	_	_
3	compared	_	_	VBD	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	former	_	_	JJ	_	_	_	_	_
7	study	_	_	NN	_	_	_	_	_
8	could	_	_	MD	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	due	_	_	JJ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	possible	_	_	JJ	_	_	_	_	_
13	differences	_	_	NNS	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	bioavailability	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	chosen	_	_	VBN	_	_	_	_	_
20	choline	_	_	NN	_	_	_	_	_
21	salts	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	best	_	_	JJS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	our	_	_	PRP$	_	_	_	_	_
8	knowledge	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	choline	_	_	NN	_	_	_	_	_
11	bitartrate	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	choline	_	_	NN	_	_	_	_	_
14	chloride	_	_	NN	_	_	_	_	_
15	bioavailability	_	_	NN	_	_	_	_	_
16	has	_	_	VBZ	_	_	_	_	_
17	not	_	_	RB	_	_	_	_	_
18	been	_	_	VBN	_	_	_	_	_
19	directly	_	_	RB	_	_	_	_	_
20	compared	_	_	VBN	_	_	_	_	_
21	to	_	_	IN	_	_	_	_	_
22	date	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Still	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	uptake	_	_	NN	_	_	_	_	_
5	profile	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	free	_	_	JJ	_	_	_	_	_
8	choline	_	_	NN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	current	_	_	JJ	_	_	_	_	_
12	study	_	_	NN	_	_	_	_	_
13	indicated	_	_	VBD	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	slower	_	_	JJR	_	_	_	_	_
16	increase	_	_	NN	_	_	_	_	_
17	upon	_	_	IN	_	_	_	_	_
18	phosphatidylcholine	_	_	NN	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	Superba	_	_	NN	_	_	_	_	_
21	Boost	_	_	NN	_	_	_	_	_
22	TM	_	_	NN	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	intake	_	_	NN	_	_	_	_	_
25	compared	_	_	VBN	_	_	_	_	_
26	to	_	_	TO	_	_	_	_	_
27	choline	_	_	NN	_	_	_	_	_
28	bitartrate	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	difference	_	_	NN	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	Tmax	_	_	NN	_	_	_	_	_
5	between	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	study	_	_	NN	_	_	_	_	_
8	products	_	_	NNS	_	_	_	_	_
9	could	_	_	MD	_	_	_	_	_
10	result	_	_	VB	_	_	_	_	_
11	from	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	structural	_	_	JJ	_	_	_	_	_
14	differences	_	_	NNS	_	_	_	_	_
15	between	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	choline	_	_	NN	_	_	_	_	_
18	forms	_	_	NNS	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	from	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	associated	_	_	VBN	_	_	_	_	_
23	differences	_	_	NNS	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	absorption	_	_	NN	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	metabolism	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Phosphatidylcholine	_	_	NN	_	_	_	_	_
2	and/or	_	_	IN	_	_	_	_	_
3	its	_	_	PRP$	_	_	_	_	_
4	isoforms	_	_	NNS	_	_	_	_	_
5	may	_	_	MD	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	absorbed	_	_	VBN	_	_	_	_	_
8	intact	_	_	JJ	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	can	_	_	MD	_	_	_	_	_
11	also	_	_	RB	_	_	_	_	_
12	be	_	_	VB	_	_	_	_	_
13	hydrolyzed	_	_	VBN	_	_	_	_	_
14	into	_	_	IN	_	_	_	_	_
15	phosphatidic	_	_	JJ	_	_	_	_	_
16	acid	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	free	_	_	JJ	_	_	_	_	_
19	choline	_	_	NN	_	_	_	_	_
20	by	_	_	IN	_	_	_	_	_
21	phospholipase	_	_	NN	_	_	_	_	_
22	D.	_	_	NN	_	_	_	_	_
23	Due	_	_	JJ	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	this	_	_	DT	_	_	_	_	_
26	conversion	_	_	NN	_	_	_	_	_
27	step	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	it	_	_	PRP	_	_	_	_	_
30	supposedly	_	_	RB	_	_	_	_	_
31	takes	_	_	VBZ	_	_	_	_	_
32	longer	_	_	RBR	_	_	_	_	_
33	to	_	_	TO	_	_	_	_	_
34	obtain	_	_	VB	_	_	_	_	_
35	free	_	_	JJ	_	_	_	_	_
36	choline	_	_	NN	_	_	_	_	_
37	from	_	_	IN	_	_	_	_	_
38	phosphatidylcholine	_	_	NN	_	_	_	_	_
39	compared	_	_	VBN	_	_	_	_	_
40	to	_	_	TO	_	_	_	_	_
41	choline	_	_	NN	_	_	_	_	_
42	bitartrate	_	_	NN	_	_	_	_	_
43	,	_	_	,	_	_	_	_	_
44	where	_	_	WRB	_	_	_	_	_
45	free	_	_	JJ	_	_	_	_	_
46	choline	_	_	NN	_	_	_	_	_
47	from	_	_	IN	_	_	_	_	_
48	the	_	_	DT	_	_	_	_	_
49	salt	_	_	NN	_	_	_	_	_
50	structure	_	_	NN	_	_	_	_	_
51	is	_	_	VBZ	_	_	_	_	_
52	more	_	_	RBR	_	_	_	_	_
53	rapidly	_	_	RB	_	_	_	_	_
54	available	_	_	JJ	_	_	_	_	_
55	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	findings	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	agreement	_	_	NN	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	former	_	_	JJ	_	_	_	_	_
8	findings	_	_	NNS	_	_	_	_	_
9	showing	_	_	VBG	_	_	_	_	_
10	that	_	_	IN	_	_	_	_	_
11	choline	_	_	NN	_	_	_	_	_
12	levels	_	_	NNS	_	_	_	_	_
13	after	_	_	IN	_	_	_	_	_
14	choline	_	_	NN	_	_	_	_	_
15	chloride	_	_	NN	_	_	_	_	_
16	reached	_	_	VBD	_	_	_	_	_
17	peak	_	_	NN	_	_	_	_	_
18	levels	_	_	NNS	_	_	_	_	_
19	earlier	_	_	RBR	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	were	_	_	VBD	_	_	_	_	_
22	reduced	_	_	VBN	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	baseline	_	_	NN	_	_	_	_	_
25	earlier	_	_	RBR	_	_	_	_	_
26	than	_	_	IN	_	_	_	_	_
27	after	_	_	IN	_	_	_	_	_
28	phosphatidylcholine	_	_	NN	_	_	_	_	_
29	intake	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	where	_	_	WRB	_	_	_	_	_
32	levels	_	_	NNS	_	_	_	_	_
33	remained	_	_	VBD	_	_	_	_	_
34	elevated	_	_	VBN	_	_	_	_	_
35	for	_	_	IN	_	_	_	_	_
36	12	_	_	CD	_	_	_	_	_
37	h.	_	_	.	_	_	_	_	_

